findmyKOL
Clinical trialNCT02743819Active, not recruitingPhase 2Interventional

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

SponsorUniversity of ChicagoEnrollment70Melanoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of South Alabama

    Mobile, Alabama, United States

  • Mount Sinai Medical Center of Florida

    Miami Beach, Florida, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, United States

  • University of Chicago

    Chicago, Illinois, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, United States

  • Northshore University Healthsystem

    Evanston, Illinois, United States

  • Oncology Specialists S.C.

    Park Ridge, Illinois, United States

  • Illinois Cancer Care

    Peoria, Illinois, United States

  • Fort Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana, United States

  • Virginia Commonwealth University/ Massey Cancer Center

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Jun 2016
Primary completion
1 Jun 2022
Completion
30 Jun 2026
Last update posted
10 Jun 2025
Registered enrollment
70
Registry id
NCT02743819

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.